The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Voyager Therapeutics Inc. (NASDAQ:VYGR) is one of the 10 best stocks under $10 offering more than 50% upside.

Back on June 1, Voyager Therapeutics Inc. (NASDAQ:VYGR) received FDA approval for VY1706, a gene therapy for Alzheimer's that targets extracellular and intracellular tau. The company had previously submitted an Investigational New Drug (IND) application, and this recent clearance will allow Voyager to begin VY1706 clinical trials on individuals with preliminary symptoms of Alzheimer's. Dosages are projected to start during the last 6 months of 2026.

Pressmaster/Shutterstock.com

The company CEO, Alfred W. Sandrock, reflected favorably on this development that followed a thorough preclinical process. He emphasized how reducing tau can be a crucial step in curing Alzheimer's. Sandrock stated:

"The IND clearance for VY1706 is the first for a tau-targeted gene therapy and follows a comprehensive preclinical program demonstrating a compelling pharmacology and safety profile. Recent third-party data continue to suggest that tau is the next critical target in Alzheimer's disease, and that reducing tau production holds promise. We view VY1706 as leading the next generation of tau targeting treatments; it is designed to durably reduce tau protein levels in key brain regions following a single IV administration."

The company shared that siRNA is the core of VY1706 and targets MAPT mRNA to lower extracellular and intracellular tau levels in the brain. As a vectorized core, it is embedded into a TRACER AAV capsid that utilizes ALPL to direct siRNA towards the brain.

Voyager Therapeutics Inc. (NASDAQ:VYGR) is a biotechnology company. It is involved in human genetics to cure neurological diseases. The product pipeline offered by this company includes VY1706, TRACER, ALPL-VYGR-NeuroShuttle, and VY7523. The company also offers a research program to cure Huntington's disease.

While we acknowledge the potential of VYGR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.